AOL Money & Finance

Options update 12-31-07: Salix volatility jumps on generic Colazal plans

Posted Dec 31st 2007 8:55AM by Paul FosterPaul Foster RSS Feed
Filed under: Options

More

Salix (NASDAQ: SLXP) has announced it will launch a generic version of its Colazal (treatment for ulcerative colitis) with Watson Pharma (NYSE: WPI). Mylan (NYSE: MYL), Apotex, and Roxane have received FDA clearance to market their own generic versions of SLXP's Colazal.

SLXP is recently down $1.01 to $8.00 in pre-open trading. Wachovia says, "Valuation range: $9 to $10."

SLXP January option implied volatility of 104 is above its 26-week average of 72 according to Track Data, suggesting larger risk.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Tags: Colazal, drugs, FDA, generic drugs, GenericDrugs, inthenews, option implied volatility, OptionImpliedVolatility, pharma, Salix, Wachovia

Symbol Lookup
IndexesChangePrice
DJIA-43.3810,407.57
NASDAQ-11.532,164.48
S&P 500-3.241,103.00

Last updated: November 24, 2009: 12:03 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

  • My Portfolio
  • Create a New Portfolio

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines